Sangamo Therapeutics (SGMO) to Release Earnings on Monday

Key Points

• Q1 2026 results on May 11: Sangamo will report earnings after the market close on Monday, May 11, 2026; analysts expect EPS of $0.0050 and revenue of $33.725 million, with a conference call at 6:30 PM ET.
• Shares traded at $0.18 on Monday with unusually high volume (61.7M vs. average 7.82M), a 52-week range of $0.12–$0.77, and a market cap of $74.98 million, highlighting a low-priced, volatile stock.
• Market sentiment is negative overall — MarketBeat consensus rates the stock as "Reduce" with a $5.50 target (1 Buy, 1 Hold, 2 Sell) — and insiders recently sold a large block (SVP sold 345,942 shares), while institutions own 56.92% of shares.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) is expected to post its Q1 2026 results after the market closes on Monday, May 11th. Analysts expect Sangamo Therapeutics to post earnings of $0.0050 per share and revenue of $33.7250 million for the quarter. Individuals can find conference call details on the company's upcoming Q1 2026 earning report page for the latest details on the call scheduled for Monday, May 11, 2026 at 6:30 PM ET.

Sangamo Therapeutics Price Performance

NASDAQ SGMO traded up $0.05 on Monday, hitting $0.18. 61,738,913 shares of the company's stock were exchanged, compared to its average volume of 7,822,592. The firm's 50-day moving average price is $0.32 and its two-hundred day moving average price is $0.41. Sangamo Therapeutics has a fifty-two week low of $0.12 and a fifty-two week high of $0.77. The firm has a market cap of $74.98 million, a price-to-earnings ratio of -0.41 and a beta of 1.04.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the company. Wall Street Zen cut Sangamo Therapeutics to a "strong sell" rating in a research report on Saturday, January 31st. Weiss Ratings reiterated a "sell (e+)" rating on shares of Sangamo Therapeutics in a research report on Thursday, January 22nd. HC Wainwright reiterated a "buy" rating and set a $10.00 target price on shares of Sangamo Therapeutics in a research report on Tuesday, February 10th. Finally, Zacks Research cut Sangamo Therapeutics from a "hold" rating to a "strong sell" rating in a report on Thursday, April 16th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of "Reduce" and a consensus price target of $5.50.

Insider Buying and Selling at Sangamo Therapeutics

In related news, SVP Nathalie Dubois-Stringfellow sold 345,942 shares of the company's stock in a transaction that occurred on Tuesday, April 21st. The stock was sold at an average price of $0.26, for a total value of $89,944.92. Following the sale, the senior vice president owned 332,769 shares in the company, valued at $86,519.94. This represents a 50.97% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 4.10% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Sangamo Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Cetera Investment Advisers acquired a new stake in shares of Sangamo Therapeutics in the 4th quarter worth approximately $31,000. XTX Topco Ltd acquired a new stake in shares of Sangamo Therapeutics in the 2nd quarter worth approximately $41,000. Engineers Gate Manager LP grew its holdings in shares of Sangamo Therapeutics by 101.7% in the 2nd quarter. Engineers Gate Manager LP now owns 87,425 shares of the biopharmaceutical company's stock worth $47,000 after acquiring an additional 44,078 shares during the period. Prelude Capital Management LLC acquired a new stake in shares of Sangamo Therapeutics in the 3rd quarter worth approximately $67,000. Finally, State of Wyoming acquired a new stake in shares of Sangamo Therapeutics in the 4th quarter worth approximately $47,000. Institutional investors and hedge funds own 56.92% of the company's stock.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc is a clinical-stage biotechnology company headquartered in Brisbane, California, that specializes in the development of genomic therapies based on its proprietary zinc finger nuclease (ZFN) technology. Founded in 1995, Sangamo pioneered ZFN-based genome editing to precisely alter DNA sequences for the treatment of serious genetic and rare diseases. The company's platform encompasses in vivo genome editing, ex vivo cell therapy, and genome regulation approaches, with a focus on durable therapeutic effects through permanent genetic modification or sustained gene expression control.

Through its genome editing programs, Sangamo is advancing multiple product candidates into clinical trials for conditions such as hemophilia A and B, mucopolysaccharidosis types I and II, and lysosomal storage disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.